| 周秀芳,杨彩哲,徐 波,李小红,刘朝阳.银杏叶联合瑞舒伐他汀对糖尿病合并脑梗死患者血清TNF-α, hs-CRP及血脂水平的影响[J].,2017,17(10):1870-1873 |
| 银杏叶联合瑞舒伐他汀对糖尿病合并脑梗死患者血清TNF-α, hs-CRP及血脂水平的影响 |
| Effects of Ginkgobiloba and Rosuvastatin on Serum Levels of TNF-α, hs-CRP and Blood Lipid of Patients with Diabetes and Cerebral Infarction |
| 投稿时间：2016-11-05 修订日期：2016-11-24 |
| DOI：10.13241/j.cnki.pmb.2017.10.018 |
| 中文关键词: 脑梗死 糖尿病 TNF-α hs-CRP |
| 英文关键词: Cerebral infarction Diabetes TNF-α hs-CRP |
| 基金项目: |
|
| 摘要点击次数: 217 |
| 全文下载次数: 90 |
| 中文摘要: |
| 摘要 目的：探讨银杏叶联合瑞舒伐他汀对糖尿病合并脑梗死的临床疗效。方法：选取2012年5月-2015年5月我院收治的糖尿病合并脑梗死患者98例，根据治疗方法不同分为对照组和研究组，每组49例。对照组采用瑞舒伐他汀钙片治疗，研究组在对照组基础上加用银杏叶提取物治疗。观察并比较两组患者治疗前后血清TNF-α，hs-CRP及血脂水平的变化情况以及临床疗效。结果：与治疗前比较，两组患者治疗后血清TNF-α水平均降低，且研究组低于对照组，差异具有统计学意义（P<0.05）；与治疗前比较，两组患者治疗后血清hs-CRP水平均降低，且研究组低于对照组，差异具有统计学意义（P<0.05）；治疗后两组患者TC，LDL-C及TG均低于治疗前，且研究组低于对照组，差异具有统计学意义（P＜0.05）；治疗后两组患者HDL-C显著高于治疗前，且研究组高于对照组，差异具有统计学意义（P＜0.05）。与治疗前比较，两组患者治疗后NIHSS评分均降低，且研究组低于对照组，差异具有统计学意义（P<0.05）。结论：银杏叶提取物联合瑞舒伐他汀治疗脑梗死合并糖尿病具有显著的临床疗效，能够降低患者血清炎症因子水平，改善患者高血脂状态，值得临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effect of ginkgobiloba combined with rosuvastatin on the treatment of diabetes and cerebral infarction. Methods: 98 cases with diabetes and cerebral infarction who were treated in our hospital from May 2012 to May 2015 were selected and according to the different treatment methods, the patients were divided into the control group and the study group, with 49 cases in each group. The patients in the control group were treated with rosuvastatin calcium tablets, while the patients in the study group were treated with ginkgobiloba on the basis of the control group. Then the serum levels of TNF-α, hs-CRP and blood lipid and the clinical efficacy in the two groups were observed and compared before and after the treatment. Results: Compared with before treatment, the serum levels of TNF-α in the two groups decreased after the treatment, and the study group was lower than that of the control group, and the differences were statistically significant (P<0.05); Compared with before treatment, the serum levels of hs-CRP decreased in the two groups after the treatment, and the study group was lower than that of the control group, and the differences were statistically significant (P<0.05); Compared with before treatment, the levels of TC, LDL-C and TG decreased after the treatment, and the study group was lower than that of the control group, and the differences were statistically significant (P<0.05); Compared with before treatment, the levels of HDL-C increased after the treatment, and the study group was higher than that of the control group, and the differences were statistically significant (P<0.05). Compared with before treatment, the NIHSS scores of the two groups decreased after the treatment, and the study group was lower than that of the control group, and the differences were statistically significant (P<0.05). Conclusion: Ginkgobiloba combined with rosuvastatin has significant clinical efficacy on the treatment of cerebral infarction with diabetes, which can reduce the levels of serum inflammatory factors in patients and decrease the high levels of blood lipids, and it is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
